glp 1 agonist wegovy Novo's becomes first GLP-1 drug approved for MASH The obesity drug semaglutide (Wegovy)

Not for use during pregnancy or nursing without guidance from your provider

SAN DIEGO(March 10, 2025)Glucagon-like peptide-1 receptor agonists (GLP-1 agonists), such as semaglutide (e.g., Ozempic), have helped improve the management of type 2 diabetes and obesity

Summary Retatrutide, a triple agonist now in phase 3 trials, has the potential to become the most effective pharmacological treatment for obesity while also offering substantial benefits in T2D management and other cardiometabolic risk factors.

Prescription compounded semaglutide tablets with personalized care from doctors

A reminder that their story doesnt start in Hollywood